Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Erik Fyrwald
AddedMar 31, 2024
UpdatedMay 31, 2026
Erik Fyrwald

Erik Fyrwald

Board Member, Syngenta

Crunchbase

Erik Fyrwald's Career

Syngenta
Syngenta

Basel, Basel-Stadt, CH

Board Member· Board
Syngenta Group
Syngenta Group

Basel, Basel-Stadt, CH

Board Member· Board
Syngenta Ventures
Syngenta Ventures

Basel, Basel-Stadt, CH

CEO· C-Suite · Management
Eli Lilly and Company
Eli Lilly and Company
Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Erik Fyrwald's Career

Syngenta
Syngenta
Public37.7k2000Basel, Basel-Stadt, CH
Board Member· Board

Recent news

Fermata uses computer vision to detect diseases and pests in plantsTechCrunch · 2025

Leadership at Syngenta

Bob WoodsBob WoodsBoard Member
Konstantin BeldyushkinKonstantin BeldyushkinCEO
AstraZenecaAstraZenecaCo-Founder
NovartisNovartisCo-Founder
Herr Gaoning NingHerr Gaoning NingBoard Member
Juliette BuiterJuliette BuiterBoard Member
Syngenta Group
Syngenta Group
53k2020Basel, Basel-Stadt, CH
Board Member· Board

Leadership at Syngenta Group

Jeff RoweJeff RoweCEO
Syngenta Ventures
Syngenta Ventures
10k2000Basel, Basel-Stadt, CH
CEO· C-Suite · Management

Similar to Syngenta Ventures

SyngentaSyngentaBasel, Basel-Stadt, CHCrop Protection, Seedsest. 2000SyngentaBasel, Basel-Stadt, CH · est. 2000

Syngenta, a Swiss agri-tech giant, empowers farmers globally with innovative solutions for sustainable, high-yield crop production.

Public37.7k
Syngenta GroupSyngenta GroupBasel, Basel-Stadt, CHPesticides, Seedsest. 2020Syngenta GroupBasel, Basel-Stadt, CH · est. 2020

Syngenta AG, a ChemChina enterprise, provides advanced agricultural science, seeds, and pesticides.

53k
Yara Growth VenturesYara Growth VenturesOslo, Oslo, NOest. 2021Yara Growth VenturesOslo, Oslo, NO · est. 2021

Yara Growth Ventures: The corporate venture capital arm of Yara International ASA.

8
Eli Lilly and Company
Eli Lilly and Company
Public39k1876
Board Member· Board

Leadership at Eli Lilly and Company

Katherine BaickerKatherine BaickerBoard Member
Ralph AlvarezRalph AlvarezBoard Member
Gabrielle SulzbergerGabrielle SulzbergerBoard Member
Juan Ricardo LucianoJuan Ricardo LucianoBoard Member
Kathi SeifertKathi SeifertBoard Member
Jamere JacksonJamere JacksonBoard Member

Similar to Eli Lilly and Company

Triveni BioTriveni BioWatertown, MA, USAntibodies, Therapeuticsest. 2023Triveni BioWatertown, MA, US · est. 2023

Triveni Bio develops first-in-class antibody therapeutics for immunological and inflammatory disorders using a genetics-informed approach.

Series C · $272M6
AbbVieAbbVieNorth Chicago, IL, USPharmaceuticalsest. 2013AbbVieNorth Chicago, IL, US · est. 2013

Innovative pharmaceuticals for various health conditions.

Public · $250k50k

Erik Fyrwald's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailLars Rebien SørensenLars Rebien SørensenBoard Member · Thermo Fisher thMartin HarrisMartin HarrisBoard Member · Thermo Fisher th

People Similar to Erik Fyrwald

Stephen GillettStephen GillettBoard Member · DiscordRodney RogersRodney RogersCo-Founder · Blue Lagoon CapitalChad RichisonChad RichisonBoard Member · Paycom SoftwareBernard DavitianBernard DavitianBoard Member · Lysosomal TherapeuticsGuillaume CeruttiGuillaume CeruttiCEO · Christie'sHoward P. KernHoward P. KernBoard Member · Sentara Healthcare